Flanvotumab
From Wikipedia, the free encyclopedia
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | HGF |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6470H9986N1714O2018S46 |
Molar mass | 145545.80 g·mol−1 |
NY (what is this?) |
Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.[1] It targets TYRP1.[2]
Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.[2]
References[]
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.
- ^ a b "Flanvotumab". Adis Insight. Springer Nature Switzerland AG.
Monoclonal antibodies for tumors | |
---|---|
Tumor | |
|
Growth factor receptor modulators | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Angiopoietin |
| ||||||||||
CNTF |
| ||||||||||
EGF (ErbB) |
| ||||||||||
FGF |
| ||||||||||
HGF (c-Met) |
| ||||||||||
IGF |
| ||||||||||
LNGF (p75NTR) |
| ||||||||||
PDGF | |||||||||||
RET (GFL) |
| ||||||||||
SCF (c-Kit) | |||||||||||
TGFβ |
| ||||||||||
Trk |
| ||||||||||
VEGF |
| ||||||||||
Others |
|
This monoclonal antibody–related article is a stub. You can help Wikipedia by . |
- v
- t
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
- v
- t
Retrieved from ""
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Abandoned drugs
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
Hidden categories:
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- All stub articles